In This Article:
-
Proportionate EBITDAF: $506 million for the half, a 7% increase on a like-for-like basis compared to the previous period.
-
Proportionate Development EBITDAF: Loss of $28 million.
-
Proportionate CapEx: Increased by 50% to $1.2 billion.
-
Interim Dividend: $0.0725 per share, unimputed.
-
CDC EBITDAF: On track, with significant demand growth and customer negotiations.
-
One NZ EBITDAF: $304 million, a 9% increase from the prior period.
-
One NZ EBITDAF Margin: 32%, up from 30% in FY24.
-
One NZ Operating Free Cash Flows: $117 million, up $21 million from the comparable period.
-
Longroad Energy EBITDAF: Down compared to the same half last year due to previous high prices.
-
Diagnostic Imaging Earnings Growth: On track for double-digit growth despite cost pressures.
-
CapEx Guidance: Revised to $2.4 billion to $2.8 billion.
-
Debt Facilities and Liquidity: Improved financial flexibility following the June equity raise.
Release Date: November 13, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Infratil Ltd (ASX:IFT) reported a strong operating performance across its portfolio, despite challenging market conditions.
-
CDC Data Centres, the company's largest investment, continues to experience significant demand growth, leading to ongoing investment in construction and securing power and land for future projects.
-
One NZ performed well, aligning with guidance and making substantial progress on strategic priorities, contributing to a 9% increase in EBITDAF.
-
The merger of Manawa Energy and Contact Energy was announced at a significant premium, with expected strong benefits for both companies.
-
Infratil Ltd (ASX:IFT) completed a successful equity raise in June, enhancing balance sheet flexibility to support growth and shareholder value creation.
Negative Points
-
Uncertainty from the US election results poses a potential headwind for Longroad Energy, particularly concerning tariffs and green policies.
-
The investment in Console Connect was canceled, which was disappointing as the company remains positive about global next-generation connectivity platforms.
-
Proportionate development EBITDAF reported a loss of $28 million, highlighting challenges in development expenditure.
-
CDC Data Centres is trending towards the lower end of its guidance range due to shifts in project timelines.
-
The Commerce Commission charges against One NZ could pose legal and financial challenges, although the company intends to challenge the charges vigorously.
Q & A Highlights
Q: Regarding CDC, has the timeline for the 388 megawatts online by the end of FY26 changed, and does this affect the EBITDA outlook? A: The timeline for the 388 megawatts remains unchanged, and we still expect strong EBITDA growth in FY26. Some workloads have shifted, but the overall completion timeline is intact.